ATE462449T1 - Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren - Google Patents

Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren

Info

Publication number: ATE462449T1
Authority: AT; Austria
Prior art keywords: cells; tumor; tumor cells; galactosyltransferase; alpha
Prior art date: 2002-10-09

Application number

AT03779090T

Other languages

English (en)

Inventor

Charles Link

Tatiana Seregina

Gabriela Rossi

Original Assignee

Central Iowa Health System

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-09

Filing date

2003-10-09

Publication date

2010-04-15

2003-10-09 Application filed by Central Iowa Health System filed Critical Central Iowa Health System

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE462449T1 publication Critical patent/ATE462449T1/de

Links

210000004881 tumor cell Anatomy 0.000 title abstract 6
206010028980 Neoplasm Diseases 0.000 title abstract 3
238000002255 vaccination Methods 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 2
125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 abstract 1
238000001415 gene therapy Methods 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000014207 opsonization Effects 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
230000005909 tumor killing Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Environmental Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Oncology (AREA)

AT03779090T 2002-10-09 2003-10-09 Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren ATE462449T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41734302P	2002-10-09	2002-10-09
PCT/US2003/032036 WO2004032865A2 (en)	2002-10-09	2003-10-09	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Publications (1)

Publication Number	Publication Date
ATE462449T1 true ATE462449T1 (de)	2010-04-15

Family

ID=32094006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03779090T ATE462449T1 (de)	2002-10-09	2003-10-09	Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren

Country Status (13)

Country	Link
US (5)	US20040191229A1 (de)
EP (1)	EP1549353B1 (de)
JP (1)	JP4966496B2 (de)
CN (2)	CN104911210A (de)
AT (1)	ATE462449T1 (de)
AU (1)	AU2003285863A1 (de)
CA (1)	CA2501744C (de)
DE (1)	DE60331933D1 (de)
DK (1)	DK1549353T3 (de)
ES (1)	ES2341335T3 (de)
HK (1)	HK1215044A1 (de)
MX (1)	MXPA05003705A (de)
WO (1)	WO2004032865A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2439014T3 (es)	1998-02-20	2014-01-21	The University Of Miami	Complejo de péptido antigénico-proteína de choque térmico modificada
US20050201993A1 (en) *	2002-10-09	2005-09-15	Link Charles J.Jr.	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
WO2004032865A2 (en)	2002-10-09	2004-04-22	Central Iowa Health System	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20060140983A1 (en) *	2004-10-25	2006-06-29	Baylor Research Institute	Dendritic cells loaded with heat shocked melanoma cell bodies
US7820628B2 (en) *	2005-02-22	2010-10-26	University Of Massachusetts Medical School	Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7850683B2 (en) *	2005-05-20	2010-12-14	Myoscience, Inc.	Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7713266B2 (en) *	2005-05-20	2010-05-11	Myoscience, Inc.	Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7998486B2 (en)	2006-10-25	2011-08-16	Newlink Genetics Corporation	Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US9254162B2 (en) *	2006-12-21	2016-02-09	Myoscience, Inc.	Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en)	2007-02-16	2013-04-02	Myoscience, Inc.	Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
WO2009065061A1 (en)	2007-11-14	2009-05-22	Myoscience, Inc.	Pain management using cryogenic remodeling
US20100112702A1 (en) *	2008-02-25	2010-05-06	Klein Benjamin Y	Method designed to divert glucose away from the glycolytic pathway
EP2257301B1 (de)	2008-03-03	2014-01-22	The University of Miami	Auf allogenen krebszellen basierende immuntherapie
AU2009226077B2 (en)	2008-03-20	2012-04-19	University Of Miami	Heat shock protein gp96 vaccination and methods of using same
AU2009251328B2 (en) *	2008-05-30	2014-10-02	Glycofi, Inc.	Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
WO2010060026A1 (en) *	2008-11-21	2010-05-27	University Of Miami	Hiv/siv vaccines for the generation of mucosal and systemic immunity
WO2010075438A1 (en)	2008-12-22	2010-07-01	Myoscience, Inc.	Integrated cryosurgical system with refrigerant and electrical power source
EP2499260B1 (de) *	2009-11-10	2017-08-23	Nestec S.A.	Herzalterungs-biomarker und verfahren zu ihrer verwendung
US20110150934A1 (en) *	2009-12-18	2011-06-23	University Of Notre Dame	Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
EP2515916B1 (de)	2009-12-23	2016-03-09	Gradalis, Inc.	Krebsimpfstoff zur furinzerlegung und gs-csf-erweiterung (fang)
US9157084B2 (en)	2009-12-23	2015-10-13	Gradalis, Inc.	Furin-knockdown bi-functional RNA
CN105399833B (zh) *	2010-01-04	2019-09-06	Kj 生物科学有限公司	用于疫苗和诊断学的Dps融合蛋白
CN102286428A (zh) *	2011-06-04	2011-12-21	内蒙古医学院	一种在肿瘤细胞表面合成α-半乳糖苷表位并激活免疫细胞的方法
CN102716497A (zh) *	2011-07-07	2012-10-10	赵永祥	α1,3半乳糖基转移酶基因转染材料及其制备方法和应用
CA2860893A1 (en)	2012-01-13	2013-07-18	Myoscience, Inc.	Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
WO2013106859A1 (en)	2012-01-13	2013-07-18	Myoscience, Inc.	Cryogenic needle with freeze zone regulation
WO2013106860A1 (en)	2012-01-13	2013-07-18	Myoscience, Inc.	Cryogenic probe filtration system
US9017318B2 (en)	2012-01-20	2015-04-28	Myoscience, Inc.	Cryogenic probe system and method
CN102760208B (zh) *	2012-07-03	2015-07-29	清华大学	基于模拟疫苗的动态人工免疫故障诊断方法
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
HK1220693A1 (zh) *	2013-03-15	2017-05-12	Newlink Genetics Corporation	碳水化合物改性的糖蛋白及其用途
US10016229B2 (en)	2013-03-15	2018-07-10	Myoscience, Inc.	Methods and systems for treatment of occipital neuralgia
US9295512B2 (en)	2013-03-15	2016-03-29	Myoscience, Inc.	Methods and devices for pain management
US9610112B2 (en)	2013-03-15	2017-04-04	Myoscience, Inc.	Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
EP2967706B1 (de)	2013-03-15	2021-09-08	Pacira CryoTech, Inc.	Stumpfe kryogene dissektionssonden
AU2014265342A1 (en) *	2013-05-15	2016-01-21	Newlink Genetics Corporation	Correlates of efficacy relating to tumor vaccines
WO2015069792A1 (en)	2013-11-05	2015-05-14	Myoscience, Inc.	Secure cryosurgical treatment system
TWI864340B (zh) *	2014-10-10	2024-12-01	美商艾爾妮蘭製藥公司	用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
KR20170109582A (ko)	2015-02-06	2017-09-29	히트 바이오로직스, 인코퍼레이티드	벡터 공동 발현 백신 및 공동 자극 분자
GB201505860D0 (en) *	2015-04-07	2015-05-20	Agalimmune Ltd	Therapeutic compositions and methods of use for treating cancer
EP4349396A3 (de)	2016-05-13	2024-05-01	Pacira CryoTech, Inc.	Systeme zur lokalisierung und behandlung mit kältetherapie
CA3040123A1 (en)	2016-10-11	2018-04-19	University Of Miami	Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en)	2017-04-04	2023-01-10	Heat Biologics, Inc.	Intratumoral vaccination
WO2019055620A1 (en) *	2017-09-13	2019-03-21	Stc. Unm	SILICIFIED CELL REPLICAS, METHODS OF MANUFACTURE, AND METHODS OF USE
US11134998B2 (en)	2017-11-15	2021-10-05	Pacira Cryotech, Inc.	Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods
WO2020185449A1 (en)	2019-03-08	2020-09-17	Stc.Unm	Silicified immunogenic cells, methods of making, and methods of using
KR20210012966A (ko) *	2019-07-24	2021-02-03	주식회사 에스엘바이젠	불사화된 줄기세포주의 제조 방법 및 이의 용도
JP2023504659A (ja) *	2019-12-03	2023-02-06	ニューボーゲン，インコーポレイティド	腫瘍細胞ワクチン
EP4087920A4 (de) *	2020-01-10	2024-02-28	The University of Hong Kong	Alpha-1,3-galactosyltransferase exprimierende rekombinante viren und ihre verwendung
US20230149456A1 (en) *	2020-03-30	2023-05-18	Unm Rainforest Innovations	Nanoparticle-loaded silicified cells, methods of making, and methods of use
US20230000963A1 (en) *	2021-06-02	2023-01-05	Neuvogen, Inc.	Tumor cell vaccines
CN120702958B (zh) *	2025-08-15	2025-11-04	细胞生态海河实验室	判断异源细胞、组织或器官间免疫排斥反应水平的方法
CN120718864B (zh) *	2025-08-28	2025-11-28	山东农业大学	一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5879675A (en) *	1994-03-15	1999-03-09	Medical College Of Pennsylvania And Hahnemann University	Compositions and methods for vaccines comprising α-galactosyl epitopes
US6218166B1 (en)	1994-12-09	2001-04-17	John Wayne Cancer Institute	Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998006746A2 (en) *	1996-08-16	1998-02-19	The Johns Hopkins University School Of Medicine	Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
US5869035A (en) *	1996-11-13	1999-02-09	Human Gene Therapy Research Institute	Methods and compositions for inducing complement destruction of tissue
WO2000009140A1 (en) *	1997-07-24	2000-02-24	Thomas Jefferson University	Composition and method of using tumor cells
US7005126B1 (en) *	1999-06-08	2006-02-28	Human Gene Therapy Research Institute	Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US7101543B2 (en) *	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
WO2002042468A2 (en) *	2000-11-27	2002-05-30	Geron Corporation	Glycosyltransferase vectors for treating cancer
US20050201993A1 (en) *	2002-10-09	2005-09-15	Link Charles J.Jr.	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
WO2004032865A2 (en)	2002-10-09	2004-04-22	Central Iowa Health System	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

2003
- 2003-10-09 WO PCT/US2003/032036 patent/WO2004032865A2/en not_active Ceased
- 2003-10-09 ES ES03779090T patent/ES2341335T3/es not_active Expired - Lifetime
- 2003-10-09 EP EP03779090A patent/EP1549353B1/de not_active Expired - Lifetime
- 2003-10-09 DK DK03779090.4T patent/DK1549353T3/da active
- 2003-10-09 JP JP2004543606A patent/JP4966496B2/ja not_active Expired - Fee Related
- 2003-10-09 CN CN201510381454.2A patent/CN104911210A/zh active Pending
- 2003-10-09 AT AT03779090T patent/ATE462449T1/de active
- 2003-10-09 MX MXPA05003705A patent/MXPA05003705A/es active IP Right Grant
- 2003-10-09 AU AU2003285863A patent/AU2003285863A1/en not_active Abandoned
- 2003-10-09 CA CA2501744A patent/CA2501744C/en not_active Expired - Fee Related
- 2003-10-09 US US10/682,178 patent/US20040191229A1/en not_active Abandoned
- 2003-10-09 DE DE60331933T patent/DE60331933D1/de not_active Expired - Lifetime
- 2003-10-09 CN CNA2003801011520A patent/CN1756568A/zh active Pending
2006
- 2006-09-19 US US11/533,199 patent/US20070014775A1/en not_active Abandoned
- 2006-09-19 US US11/533,184 patent/US7763461B2/en not_active Expired - Fee Related
2010
- 2010-09-09 US US12/878,756 patent/US8535658B2/en not_active Expired - Fee Related
2013
- 2013-08-14 US US13/966,446 patent/US9474801B2/en not_active Expired - Fee Related
2016
- 2016-03-14 HK HK16102936.5A patent/HK1215044A1/zh unknown

Also Published As

Publication number	Publication date
WO2004032865A2 (en)	2004-04-22
ES2341335T3 (es)	2010-06-18
CN1756568A (zh)	2006-04-05
JP4966496B2 (ja)	2012-07-04
EP1549353B1 (de)	2010-03-31
DK1549353T3 (da)	2010-07-12
CA2501744A1 (en)	2004-04-22
US20040191229A1 (en)	2004-09-30
WO2004032865A3 (en)	2004-06-10
US20070014775A1 (en)	2007-01-18
US7763461B2 (en)	2010-07-27
DE60331933D1 (de)	2010-05-12
US20070014774A1 (en)	2007-01-18
WO2004032865A9 (en)	2004-07-22
US20110250233A1 (en)	2011-10-13
EP1549353A2 (de)	2005-07-06
AU2003285863A1 (en)	2004-05-04
US20140037692A1 (en)	2014-02-06
US8535658B2 (en)	2013-09-17
CA2501744C (en)	2012-01-03
HK1215044A1 (zh)	2016-08-12
JP2006507267A (ja)	2006-03-02
CN104911210A (zh)	2015-09-16
AU2003285863A8 (en)	2004-05-04
MXPA05003705A (es)	2005-08-16
US9474801B2 (en)	2016-10-25

Legal Events

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1549353

Country of ref document: EP

Publication	Publication Date	Title
DE60331933D1 (de)	2010-05-12	Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
Weiner et al.	1999	Genetic vaccines
YoungáKim et al.	2020	Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy
WO2008057235A3 (en)	2008-08-07	Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
CY1113394T1 (el)	2016-06-22	Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια
IL173481A0 (en)	2006-06-11	Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
Noh et al.	2014	GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity
IL176007A0 (en)	2006-10-05	Antibodies specific to c35 and pharmaceutical compositions containing the same
Appelbe et al.	2017	Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide
Klimek et al.	2014	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs
ATE287958T1 (de)	2005-02-15	Verbesserte krebstherapie
ATE228016T1 (de)	2002-12-15	Lebendvakzine zur behandlung von tumorerkrankungen
DE60137146D1 (de)	2009-02-05	Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
CA2233015A1 (en)	1997-04-03	Therapeutic applications using horse serum
Macedo et al.	2016	Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Park et al.	2020	A novel cancer immunotherapy utilizing autologous tumour tissue
CN107213479A (zh)	2017-09-29	一种包含过氧化氢酶的组合物及用途
MXPA05010804A (es)	2006-03-09	Torio 227 para uso en radioterapia de enfermedades del tejido blando.
Gupta et al.	2016	Periodontal vaccine: A new vista in periodontology-A review
ES2968843T3 (es)	2024-05-14	Molécula de ARNm y agente fotosensibilizador para uso médico
CN113117088A (zh)	2021-07-16	钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用
JP7034521B1 (ja)	2022-03-14	がんワクチン及びがんワクチンの製造方法
US20230321230A1 (en)	2023-10-12	Compositions and Methods for Adjuvanted Vaccines
Sarantopoulos	2022	Breaking B-Cell Tolerance to Produce Antibodies that Eradicate Leukemias and Lymphomas
Hillery	2024	MRNA Therapeutics: Foundations, Innovations, and Clinical Applications